CTLA4 and neoplasm: In previous studies (20, 21), it has been shown that although intratumoral injection of AMPs can prime the response of tumor-specific T-cells; it is because of the presence of immune checkpoints such as PD-L1 or CTLA-4 on the tumor surface, primed specific T cells can be exhausted.